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OBJECTIVE—Lipoprotein-associated phospholipase A2 (Lp-
PLA2) has been shown to be associated with increased risk of
coronary heart disease (CHD) in general adult populations.
Because men and women with type 2 diabetes are at particularly
high risk for CHD, the aim of this study was to assess the
association of Lp-PLA2 with future coronary events among
diabetic men and women.
RESEARCH DESIGN AND METHODS—We measured Lp-
PLA2 activity among 740 men and 777 women with conﬁrmed
diabetes enrolled in the Health Professionals Follow-Up Study
(HPFS) and Nurses’ Health Study (NHS). Participants were free
of all cardiovascular disease and cancer at baseline.
RESULTS—During 10 years of follow-up among men and 14
years among women, we documented 178 and 146 cases of CHD,
respectively. We deﬁned CHD as coronary artery bypass graft,
angioplasty, nonfatal myocardial infarction, and fatal CHD. After
adjustment for age, smoking, medical history, and biomarkers
including C-reactive protein, HDL, and LDL, the relative risk of
total CHD comparing extreme tertiles of Lp-PLA2 was 1.39 (95%
CI 1.01–1.90; P trend  0.03). When we restricted analyses to only
nonfatal myocardial infarction and fatal CHD, the relative risk
was 1.75 (95% CI 1.05–2.92; P for trend  0.001). LDL, HDL,
C-reactive protein, hormone replacement therapy use, and dia-
betes duration did not modify these relationships.
CONCLUSIONS—Levels of Lp-PLA2 activity were signiﬁcantly
associated with incident CHD among men and women with type
2 diabetes, independent of traditional and inﬂammatory risk
factors. This positive association was strongest for more severe
clinical end points. Diabetes 59:1239–1243, 2010
D
iabetic subjects have a two- to fourfold in-
creased risk of heart disease (1), but the mech-
anism through which this increased risk is
mediated is not fully understood. Inﬂammatory
processes have been increasingly recognized as a critical
step in the pathogenesis of both diabetes and heart disease
and may offer a biological link between the two diseases
(2). One newly recognized inﬂammatory biomarker is
lipoprotein-associated phospholipase A2 (Lp-PLA2), an en-
zyme that may inﬂuence atherogenesis and plaque rupture
without altering the general immune response (3).
Recent evidence from large long-term epidemiological
studies suggests that elevated levels of Lp-PLA2 are asso-
ciated with risk of coronary heart disease (CHD) (4–10).
To date, no study has had sufﬁcient power to examine this
association among diabetic subjects, who may represent a
particularly high-risk group. The aim of this study is to
examine the effect of Lp-PLA2 activity on future coronary
heart disease among male and female type 2 diabetic
subjects.
RESEARCH DESIGN AND METHODS
Study population. The Health Professionals Follow-up Study (HPFS) and
Nurses’ Health Study (NHS) are prospective cohort studies of 51,529 men and
121,700 women, respectively. The present study includes 740 men and 777
women with diabetes who were free of cancer and cardiovascular disease at
blood draw, and who had detectable Lp-PLA2 activity values. These cohorts
have been described in detail elsewhere (11,12).
Deﬁnition of diabetes and cardiovascular end points. Participants who
indicated a diagnosis of diabetes on any biennial follow-up questionnaire were
sent a supplementary questionnaire to conﬁrm diabetes. We used the National
Diabetes Data Group criteria (13) to deﬁne diabetes because our participants
were diagnosed before the American Diabetes Association released their
criteria in 1997. Diabetes was conﬁrmed in subsamples from the HPFS (97%
conﬁrmed) and the NHS (98% conﬁrmed) (14,15).
CHD end points were coronary artery bypass graft surgery or percutaneous
transluminal coronary angioplasty (CABG/PTCA), nonfatal myocardial infarc-
tion (MI), and fatal CHD. If participants experienced multiple CHD events
during follow-up, they were assigned the more severe clinical event, but
censored at the date of the ﬁrst event. Further information about diabetes and
CHD diagnoses has been provided previously (11,12) and is provided in the
supplementary information (available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-0730/DC1).
Blood collection and laboratory measurements. Lp-PLA2 activity was
measured by a colorimetric activity test automated assay performed on a
clinical chemistry analyzer using a colorimetric substrate for Lp-PLA2 (7). All
samples were run in duplicate with a mean coefﬁcient of variation (CV) of
4.9%. Lp-PLA2 concentration was measured with an enzyme-linked immuno-
assay (PLAC test; diaDexus, San Francisco, CA). Other biomarker measure-
ments are described in the supplementary methods. In this study, there was a
moderate and statistically signiﬁcant correlation between concentration and
activity (r  0.30, P  0.001, among women; r  0.29, P  0.001, among men).
In preliminary analyses, Lp-PLA2 concentration was not associated with
incident coronary heart disease (data not shown), indicating that Lp-PLA2
activity may be the more biologically relevant parameterization of Lp-PLA2. All
subsequent analyses therefore focused on Lp-PLA2 activity.
Statistical analysis. Follow-up began at the month of blood draw and
continued either until June 2004, CHD event, or death. We used Cox
proportional hazards analysis stratiﬁed by 5-year age categories over each
2-year follow-up period to estimate relative risks (RRs) and 95% CIs for tertiles
of Lp-PLA2 activity. Tests for trend were estimated across median values of
Lp-PLA2 tertile. To assess predictive ability, we calculated the area under the
receiver-operating characteristic curves for multivariable-adjusted models
with and without Lp-PLA2 activity included. We assessed potential effect
modiﬁcation by modeling joint effects of Lp-PLA2 tertile and tertiles of LDL,
HDL, C-reactive protein, hormone replacement therapy use, and duration of
diabetes. We then compared models with and without a cross-classiﬁcation
From the
1Departments of Nutrition and Epidemiology, Harvard School of
Public Health, Boston, Massachusetts; the
2Channing Laboratory, Depart-
ment of Medicine, Brigham and Women’s Hospital and Harvard Medical
School, Boston, Massachusetts; and
3Worldwide Epidemiology, Glaxo-
SmithKline, Research Triangle Park, North Carolina.
Corresponding author: Eric B. Rimm, erimm@hsph.harvard.edu.
Received 14 May 2009 and accepted 15 February 2010. Published ahead of
print at http://diabetes.diabetesjournals.org on 25 February 2010. DOI:
10.2337/db09-0730.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
BRIEF REPORT
diabetes.diabetesjournals.org DIABETES, VOL. 59, MAY 2010 1239term using 2 log likelihood tests. If there was absence of heterogeneity of
results between the NHS and HPFS as assessed by the Q-statistic, we pooled
results by weighing each estimate by the inverse of its variance (STATA;
StataCorp, College Station, TX). All other analyses were performed using SAS
statistical software (SAS Institute, Cary, NC).
RESULTS
During 8,010 person-years of follow-up in the men, 178
cases of CHD occurred, including 64 cases of nonfatal MI
and fatal CHD and 114 CABG/PTCA. In the women, 146
cases of CHD occurred during 9,643 person-years of
follow-up, including 73 cases of nonfatal MI and fatal CHD
and 73 cases of CABG/PTCA. Among both men and
women, smoking and less aspirin use were related to
higher levels of Lp-PLA2 activity. Additionally, among
women only, history of hypertension and family history of
heart disease were positively associated, and postmeno-
pausal hormone use was inversely associated with Lp-
PLA2 activity (Table 1). In addition, shorter duration of
diabetes was associated with higher Lp-PLA2 activity. In
both men and women, Lp-PLA2 activity was positively
associated with LDL and intercellular adhesion molecule
and inversely associated with HDL (supplementary Table
1, available in the online appendix).
We calculated the relative risk associated with tertiles of
Lp-PLA2 activity for speciﬁc CHD end points and for total
CHD (Table 2). With no differences in risk estimates
between sexes, we pooled the results from the two studies
(Q  0.12, P  0.73 for total CHD; Q  0.15, P  0.70 for
nonfatal MI and fatal CHD; and Q  0.85, P  0.36 for
CABG/PTCA); sex-speciﬁc results are presented in supple-
mentary Tables 2 and 3. The age-adjusted RR between the
extreme tertiles of Lp-PLA2 activity was 1.93 (95% CI
1.25–2.97; P for trend  0.001) for nonfatal MI and fatal
CHD, 1.61 (1.12–2.30; P for trend  0.009) for CABG/
PTCA, and 1.76 (1.34–2.32; P  0.001) for total CHD. After
adjusting for lifestyle and clinical risk factors other than
LDL, these relative risks were only modestly attenuated.
However, after additional adjustment for LDL, the relative
risk was strongly attenuated for CABG/PTCA (RR 1.12;
95% CI 0.74–1.70), but not so for nonfatal MI and fatal
CHD (RR 1.75; 1.05–2.92). These results were slightly
stronger for fatal CHD (RR 2.01; 0.90–4.50; P for trend
0.001 for fully adjusted extreme tertiles) than nonfatal
MI (RR 1.62; 0.81–3.22; P for trend  0.002 for fully
adjusted extreme tertiles), but there was no statistically
signiﬁcant difference between these two end points
(Q  0.16; P  0.69). Lp-PLA2 activity added signiﬁ-
cantly to the area under the receiver-operating charac-
teristic curve for MI in men (P  0.02), but did not
signiﬁcantly add to predictive ability for any other end
point in men or women. Additional adjustment for
hypertension medications did not alter these results.
We next examined whether Lp-PLA2 activity is more
strongly related to cardiovascular events occurring closer
to the date of Lp-PLA2 measurement. Over the ﬁrst 6 years
of follow-up, there were 138 total cases of CHD among the
men and women, and over the next 6 years in the HPFS
and 8 years in the NHS, there were 186 total cases of CHD.
Lp-PLA2 activity was more strongly related to incident
CHD during the ﬁrst 6 years of follow-up (RR 2.00, 95% CI
1.16–3.44 for extreme tertiles) but less so after 6 years of
follow-up (1.23, 0.81–1.89) (Table 3), irrespective of type
of CHD (data not shown).
Because the risk of CHD associated with Lp-PLA2 may
vary by levels of other lifestyle and biological markers, we
tested for interactions in the combined datasets and found
no signiﬁcant or meaningful interactions with LDL, HDL,
C-reactive protein, hormone replacement therapy use, or
duration of diabetes (data not shown).
TABLE 1
Age-adjusted baseline characteristics across tertiles of Lp-PLA2 activity among 777 female type 2 diabetic subjects from the NHS and
740 male type 2 diabetic subjects from the HPFS
Tertile of Lp-PLA2
Tertile 1 Tertile 2 Tertile 3
Men Women Men Women Men Women
Lp-PLA2 mean (nmol  min
1  ml
1) 126.2 119.9 159.3 157.3 199.7 200.0
Lp-PLA2 range 60.4–146.0 56.4–141.2 146.1–173.1 141.3–172.5 173.2–391.2 172.6–343.0
Age at baseline (years) 61.4 57.0 62.1 58.3 61.4 58.7
BMI (kg/m
2) 27.9 29.4 27.6 30.4 27.8 30.4
Physical activity (MET) 28.9 43.7 28.9 20.8 27.4 28.1
Current smoker (%) 6.2 9.9 7.0 10.5 8.4 21.1
Regular aspirin use (%) 37.6 24.6 37.1 21.4 31.2 24.2
Duration of diabetes (years) 7.8 9.4 7.9 8.2 6.7 6.2
Family history of CHD (%) 36.3 23.0 35.0 21.3 35.4 28.3
History of hypertension (%) 42.6 55.1 45.2 62.4 45.9 64.4
History of high serum cholesterol (%) 33.3 47.0 39.5 52.9 49.6 51.8
Cholesterol-lowering medication use (%) 5.9 3.9 8.5 4.3 6.2 4.2
Postmenopausal hormone use (%) N/A 36.1 N/A 23.0 N/A 18.3
Insulin use (%) 18.8 20.1 19.9 21.1 15.5 17.7
Alcohol (g/day) 8.7 3.4 8.9 2.5 9.1 3.4
C-reactive protein (median; mg/dl) 1.4 5.0 1.9 4.8 1.8 5.4
A1C (%) 7.4 6.7 7.4 6.8 7.2 7.0
Intercellular adhesion molecule (ng/ml) 344.7 290.2 351.8 303.4 370.1 347.2
Triglycerides (mg/dl)* 189.4 174.5 169.0 185.2 193.3 203.1
LDL cholesterol (mg/dl) 110.3 122.6 127.8 140.5 141.4 155.0
HDL cholesterol (mg/dl) 43.3 59.1 41.0 51.0 37.9 46.2
*Triglycerides based on 406 men and 527 women with fasted blood samples.
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In the present study, higher levels of Lp-PLA2 activity were
associated with increased risk of incident coronary heart
disease among diabetic men and women. This is the ﬁrst
prospective study speciﬁcally to examine Lp-PLA2 and
incident CHD among diabetic subjects, and the relative
risks found in this study are similar to those from studies
that have examined general community and clinical
populations.
We found that Lp-PLA2 activity was more strongly
associated with nonfatal MI and fatal CHD than with
CABG/PTCA. It is possible that CABG/PTCA is a weaker
clinical end point, since reasons to clinically intervene
may be more subjective and less likely to be conducted in
the sickest patients. In the only other study explicitly to
investigate several different CHD outcomes, Oei et al. (9)
found virtually no difference in relative risk by outcome.
We also found that Lp-PLA2 activity was more strongly
related to cardiovascular events that occurred within the
ﬁrst 6 years of follow-up. Our study is the ﬁrst to examine
the relation between Lp-PLA2 and incident CHD stratiﬁed
by time to event in a nonclinical population. Although
Lp-PLA2 concentration has been associated with coronary
artery calciﬁcation (16,17), Lp-PLA2 activity has consis-
tently demonstrated lack of association with coronary
artery calciﬁcation (17,18). This, in combination with our
observations that both later occurrence of CHD and
CABG/PTCA were more weakly associated with Lp-PLA2,
could indicate that Lp-PLA2 activity is related to unstable
or rupture-prone lesions rather than to atherosclerosis
alone. This is supported by recent evidence from a ran-
domized trial that demonstrated that use of an Lp-PLA2
activity inhibitor decreased plaque severity over 12 weeks
(19).
In a recent investigation in the population-based Athero-
sclerosis Risk in Communities (ARIC) study, the authors
found that of 19 novel biomarkers, Lp-PLA2 concentration
was the only marker to add signiﬁcantly to the area under
the receiver operating curves, although this magnitude
was relatively small (20). This is of considerable impor-
tance for diabetic populations because of their increased
risk of CHD. In the present study, Lp-PLA2 activity added
signiﬁcantly to risk prediction for MI among men, but not
for other end points in men or women. It is possible that
our study is underpowered. Future studies with larger
populations should examine the predictive ability of Lp-
TABLE 2
Relative risk (95% CIs) of incident CHD by tertiles of Lp-PLA2 activity among 1,517 male and female diabetic subjects from the HPFS
and NHS
Tertiles of Lp-PLA2
P for trend 12 3
Nonfatal MI and fatal CHD 32 42 63
Age adjusted 1.0 1.25 (0.79–1.99) 1.93 (1.25–2.97) 0.001
Multivariate adjusted* 1.0 1.22 (0.75–1.99) 1.74 (1.10–2.76) 0.009
Multivariate adjusted  LDL 1.0 1.23 (0.75–2.01) 1.75 (1.05–2.92) 0.001
CABG/PTCA 49 58 80
Age adjusted 1.0 1.13 (0.77–1.65) 1.61 (1.12–2.30) 0.009
Multivariate adjusted* 1.0 1.11 (0.75–1.63) 1.50 (1.02–2.22) 0.040
Multivariate adjusted  LDL 1.0 0.94 (0.63–1.41) 1.12 (0.74–1.70) 0.571
Total CHD 81 100 143
Age adjusted 1.0 1.18 (0.88–1.58) 1.76 (1.34–2.32) 0.001
Multivariate adjusted* 1.0 1.15 (0.85–1.55) 1.62 (1.21–2.17) 0.001
Multivariate adjusted  LDL 1.0 1.05 (0.77–1.43) 1.39 (1.01–1.90) 0.034
Results were pooled between men and women using inverse variance weights. n  1,517. *Multivariate relative risks adjusted for age, fasting
status, smoking, alcohol intake, physical activity, duration of diabetes, aspirin use, cholesterol-lowering medication use, family history of MI,
history of hypertension, BMI, HDL, A1C, C-reactive protein, intercellular adhesion molecule, insulin use, waist circumference, estimated
glomerular ﬁltration rate, and hormone replacement therapy use (women only).
TABLE 3
Relative risk (95% CIs) of early versus late incident non-fatal MI, fatal CHD, and CABG/PCTA by tertiles of Lp-PLA2 activity among
1,517 male and female diabetic subjects from the HPFS and NHS
Tertiles of Lp-PLA2
P for trend 12 3
Total CHD within 6 years (n  1,517) 28 43 67
Age adjusted 1.0 1.70 (1.04–2.77) 2.41 (1.51–3.84) 0.001
Multivariate adjusted* 1.0 1.72 (1.03–2.86) 2.34 (1.42–3.86) 0.001
Multivariate adjusted  LDL 1.0 1.57 (0.93–2.65) 2.00 (1.16–3.44) 0.012
Total CHD after 6 years (n  1,309)† 54 54 78
Age adjusted 1.0 1.10 (0.75–1.62) 1.65 (1.15–2.37) 0.005
Multivariate adjusted* 1.0 1.10 (0.73–1.63) 1.51 (1.02–2.23) 0.039
Multivariate adjusted  LDL 1.0 0.98 (0.65–1.47) 1.23 (0.81–1.89) 0.323
Results were pooled between men and women using inverse variance weights. *Multivariate relative risks adjusted for age, fasting status,
smoking, alcohol intake, physical activity, duration of diabetes, aspirin use, cholesterol-lowering medication use, family history of MI, history
of hypertension, BMI, HDL, A1C, C-reactive protein, intercellular adhesion molecule, insulin use, waist circumference, estimated glomerular
ﬁltration rate, and hormone replacement therapy use (women only). †Follow-up began 6 years after blood draw. Participants who sustained
a nonfatal MI or fatal CHD or were lost to follow-up before year 6 were not considered at risk for a cardiovascular event after 6 years.
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risk prediction can help uncover important etiologic path-
ways for cardiovascular disease.
In this study, although Lp-PLA2 activity was associated
with incident CHD, Lp-PLA2 concentration was not. It is
possible that the diabetes-associated disruption of meta-
bolic parameters also affects Lp-PLA2 concentrations and
renders these values less informative. This will need to be
conﬁrmed in other populations. It is unclear which param-
eterization of Lp-PLA2 will ultimately be most relevant for
prediction and etiology, and future studies with both
measurements should tease out these distinct pathways.
Lp-PLA2 is hypothesized to contribute to the develop-
ment of atherosclerosis through the propagation of inﬂam-
matory processes in the arterial intima (21). Several
characteristics of Lp-PLA2 suggest that this enzyme could
be speciﬁcally relevant in people with diabetes. First,
diabetic subjects have increased circulating levels of small
dense LDL (2), potentially providing an efﬁcient vehicle for
delivery of Lp-PLA2 to the intima, since Lp-PLA2 has
apparent binding preference for small dense LDL (22).
Second, free radicals from oxidation of excess glucose
may increase the oxidation of lipoproteins (23) and
thereby increase levels of the substrate for Lp-PLA2. Third,
diabetes is characterized by increased macrophage inﬁl-
tration of the arterial wall (2). Lp-PLA2 is secreted by
macrophages, although the actual level of Lp-PLA2 produc-
tion within the artery wall is unclear (21). Finally, in addition
to diabetic and insulin-resistant conditions providing a milieu
that would foster increased Lp-PLA2 concentration and
activity, Lp-PLA2 could potentially perpetuate insulin resis-
tance through its generation of free fatty acids and increased
chemotaxis, both of which could lead to persistent chronic
inﬂammation (21,24,25).
This study has several limitations. First, although we
have a relatively large number of men and women with
diabetes in this study, we have less power to detect
relationships when stratifying by type of CHD. Second,
Lp-PLA2 was only measured at baseline, which may lead to
modest misclassiﬁcation over time. However, in a pilot
study from the Health Professionals Follow-Up Study, men
provided two samples 1 year apart, and Lp-PLA2 activity
was shown to be highly reproducible (intraclass r  0.87).
In conclusion, among male and female participants with
type 2 diabetes, Lp-PLA2 activity was an independent risk
factor for coronary heart disease, particularly for nonfatal
MI and fatal CHD. This is the ﬁrst prospective study to
document this relationship among diabetic subjects who
were free of CVD at baseline. Although the risk for CHD
potentially conferred by Lp-PLA2 among diabetic subjects
appears to be consistent with those in the general popu-
lation, further research is needed to explore whether
reduction in Lp-PLA2 reduces risk of CHD in diabetic
subjects.
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